← Catalyst calendarLGVN biotech catalysts & pipeline
LONGEVERON INC · Data as of 2026-10-27
Upcoming catalysts
laromestrocel (LOMECEL-B®) — Clinical data readout
Q4 2026
As a result of a private placement financing completed in March of 2026 (the "Private Placement"), and based on current operating plans, the Company expects that its cash and cash equivalents as of June 30, 2026, which include proceeds from the Private Placement, will be adequate to fund operations into the fourth quarter of 2026.
Source filinglaromestrocel (LOMECEL-B®) — NDA/BLA submission
2027
If the current ELPIS II trial in HLHS is successful, we believe the timing would be optimal to seek a potential BLA filing with the FDA in 2027 and commercialization partner.
Source filinglaromestrocel (LOMECEL-B®) — Conference presentation
Nov 8
Date: Sunday, November 8, 2026
Source filingExplore the free biotech catalyst calendar
